| Harrow to Present at Two Investor Conferences in May |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 25th Annual Investor Conference (The Ritz-Carlton, Marina del Rey, CA) Format: Fireside Chat, followed by 1x1 Investor Meetings Date/Time: Wednesday, May 21, 2025, through Thursday, May 22, 2025 Craig-Hallum 22nd Annual Institutional Investor Conference (Depot Rena. |
businesswire.com |
2025-05-14 11:00:00 |
Czytaj oryginał (ang.) |
| Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript |
Harrow, Inc. (NASDAQ:HROW ) Q1 2025 Results Conference Call May 9, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Chase Knickerbocker - Craig Hallum Jeffrey Cohen - Ladenburg Thalmann and Company Yi Chen - H. C. Wainwright Mayank Mamtani - B. |
seekingalpha.com |
2025-05-10 22:17:15 |
Czytaj oryginał (ang.) |
| Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates |
Harrow (HROW) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.28 per share a year ago. |
zacks.com |
2025-05-08 22:10:39 |
Czytaj oryginał (ang.) |
| Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to disc. |
businesswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| What Recession? I'm Swimming In Dividends |
What Recession? I'm Swimming In Dividends |
seekingalpha.com |
2025-04-29 11:35:00 |
Czytaj oryginał (ang.) |
| NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. |
BERWYN, Pa. , April 24, 2025 /PRNewswire/ -- Nordic Pharma, Inc., a subsidiary of Nordic Group B.V. |
prnewswire.com |
2025-04-24 14:00:00 |
Czytaj oryginał (ang.) |
| Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an expansion of its VEVYE® Access for All (“VAFA”) program to include patients currently prescribed Klarity-C Drops®, a compounded cyclosporine 0.1% product manufactured and distributed by ImprimisRx®, Harrow's compounding subsidiary. Since its launch on March 17, 2025, VEVYE Access for All has simplified dry eye therapy for eligible patients by eliminating access b. |
businesswire.com |
2025-04-10 11:00:00 |
Czytaj oryginał (ang.) |
| Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) |
Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex reimbursement challenges and tough competition. Valuation models suggest Harrow is fairly valued if it achieves 20% revenue growth and 15% FCF margins, though these are lofty expectations. |
seekingalpha.com |
2025-03-29 18:30:00 |
Czytaj oryginał (ang.) |
| Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call |
Harrow, Inc. (NASDAQ:HROW ) Q4 2024 - Earnings Conference Call March 28, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Thomas Flaten - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann and Company Mayank Mamtani - B. Riley Securities Yi Chen - H. |
seekingalpha.com |
2025-03-28 16:00:40 |
Czytaj oryginał (ang.) |
| Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp |
Harrow, Inc. is a speculative buy, with potential trading gains from the $20s to the $30s, and long-term growth prospects. The company reported strong Q4 growth, with an 84% revenue increase and improved gross profit margins, driven by key products IHEEZO and VEVYE. Harrow's 2025 revenue guidance is bullish, expecting over $280 million, a 40% increase, supported by the VEVYE Access for All program. |
seekingalpha.com |
2025-03-28 15:39:25 |
Czytaj oryginał (ang.) |
| Harrow (HROW) Q4 Earnings and Revenues Top Estimates |
Harrow (HROW) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.27 per share a year ago. |
zacks.com |
2025-03-27 21:45:32 |
Czytaj oryginał (ang.) |
| Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2024. The Company also posted its fourth quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future. |
businesswire.com |
2025-03-27 18:01:00 |
Czytaj oryginał (ang.) |
| Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its fourth quarter and audited financial results for the year ended December 31, 2024, on Thursday, March 27, 2025, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Fri. |
businesswire.com |
2025-03-27 12:45:00 |
Czytaj oryginał (ang.) |
| Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Harrow's transitional pass-through application for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocula. |
businesswire.com |
2025-03-24 09:00:00 |
Czytaj oryginał (ang.) |
| Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced unaudited preliminary financial results for the fourth quarter and year ended December 31, 2024, as well as revenue guidance for 2025. Although Harrow was initially scheduled to release its audited financial results today, the Company's new independent auditor requires additional time to audit Harrow's financial presentation. As a result, Harrow is delaying its earn. |
businesswire.com |
2025-03-17 18:01:00 |
Czytaj oryginał (ang.) |
| Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025 |
Harrow Health's robust distribution platform and patented eye care products create a strong moat, offering an attractive entry point after the recent stock price correction. Catalysts in 2025 could come from a successful Triesence launch and potential NDA filing for Melt pharma, where HROW has a material stake. The main risk is the company's loss in Q3 2024 despite recent acquisitions, so more revenue growth alongside controlled costs is needed for the stock to work from here. |
seekingalpha.com |
2025-03-01 10:50:08 |
Czytaj oryginał (ang.) |
| I Am Loading Up Big Dividends For My Golden Years |
Innovation, demand, and shortage of providers have kept healthcare inflation significantly higher than the CPI. Regardless of the political scene, the aging U.S. population and rising chronic illnesses are undeniable truths to face. Income investing ensures consistent returns, allowing flexibility in financial planning, despite volatile stock prices. |
seekingalpha.com |
2025-02-17 09:35:00 |
Czytaj oryginał (ang.) |
| Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategic partnership with Cencora (NYSE: COR). Harrow Cares delivers a comprehensive suite of high‑quality access and affordability services, enhancing support for retina specialists, their staff, and patients. Through a state-of-the-art patient support services hub, Harrow Cares ensures seamless enrollment, rapid. |
businesswire.com |
2025-01-27 09:30:00 |
Czytaj oryginał (ang.) |
| Harrow Appoints Amir H. Shojaei as Chief Scientific Officer |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophtha. |
businesswire.com |
2025-01-07 09:00:00 |
Czytaj oryginał (ang.) |
| Those Derisked Baby Bonds Of Harrow, Inc. |
Harrow's 11.875% Senior Notes due 2027 are attractive baby bonds with a healthy leverage percentage of 13.8%, indicating strong creditworthiness and low debt. Harrow funds operations through product sales, not debt or frequent equity raises, showcasing a robust financial position and sustainable business model. VEVYE, IHEEZO, and Triesence show significant growth potential, with Triesence addressing supply chain issues and justified price hikes, ensuring strong future demand. |
seekingalpha.com |
2025-01-03 17:43:10 |
Czytaj oryginał (ang.) |
| Harrow: The Triesence Relaunch |
Harrow's relaunch of Triesence, a preservative-free corticosteroid, addresses a critical unmet need in ophthalmology, offering safer and more effective treatment options for eye care professionals. Triesence's unique formulation and absence of preservatives make it superior to alternatives like Kenalog, despite its higher price point and previous supply chain issues. Harrow's acquisition and relaunch of Triesence, with 39,000 units available, positions the company for significant market growth, targeting over 500,000 units annually. |
seekingalpha.com |
2024-12-14 02:09:40 |
Czytaj oryginał (ang.) |
| Harrow Announces Participation in Upcoming Investor Conferences |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel) November 19, 2024 1x1 Meetings Only BTIG 4th Annual Ophthalmology Day (Virtual) December 2, 2024 1x1 Virtual Meetings Only Piper Sandler 36th Annual Healthcare Conference (The Lotte New York Palace) Dec. |
businesswire.com |
2024-11-15 09:00:00 |
Czytaj oryginał (ang.) |
| Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript |
Harrow, Inc. (NASDAQ:HROW ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Jamie Webb - Director, Communications & Investor Relations Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann & Company Mayank Mamtani - B. Riley Securities Operator Good morning, and welcome to Harrow's Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-11-14 16:56:52 |
Czytaj oryginał (ang.) |
| Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates |
Harrow (HROW) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago. |
zacks.com |
2024-11-13 20:45:44 |
Czytaj oryginał (ang.) |
| Harrow Announces Third Quarter 2024 Financial Results |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and f. |
businesswire.com |
2024-11-13 18:34:00 |
Czytaj oryginał (ang.) |
| Harrow: VEVYE And Its Impact On The DED Market |
Harrow Inc. experienced a brief 20% stock drop in October but quickly recovered, showing resilience despite recent revenue channel underperformance. HROW's new branded pharmaceutical products, especially VEVYE, are driving a diversified revenue stream, with VEVYE showing exceptional growth and market penetration since its late 2023 launch. VEVYE's strong refill rates and expanding prescriber base indicate significant patient benefits and long-term revenue potential, supported by a patent extending to 2039. |
seekingalpha.com |
2024-11-11 08:37:34 |
Czytaj oryginał (ang.) |
| Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable |
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-11-08 11:56:16 |
Czytaj oryginał (ang.) |
| Will Harrow (HROW) Report Negative Earnings Next Week? What You Should Know |
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-11-06 13:05:36 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for November 6th |
HROW, ORLA and SWDBY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 6, 2024. |
zacks.com |
2024-11-06 13:00:28 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for November 6th |
ORLA, SWDBY, SUOPY, HROW and CLPR have been added to the Zacks Rank #1 (Strong Buy) List on November 6, 2024. |
zacks.com |
2024-11-06 09:26:08 |
Czytaj oryginał (ang.) |
| Harrow (HROW) Upgraded to Strong Buy: What Does It Mean for the Stock? |
Harrow (HROW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-10-30 15:01:13 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Harrow (HROW) Could Rally 25.95%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Harrow (HROW). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-10-29 12:55:23 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for October 24th |
FOLD, CLPR and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2024. |
zacks.com |
2024-10-24 15:16:09 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for October 24th |
CLPR, HROW, FOLD, GTLB and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2024. |
zacks.com |
2024-10-24 12:31:16 |
Czytaj oryginał (ang.) |
| Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why |
Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
zacks.com |
2024-10-22 13:50:23 |
Czytaj oryginał (ang.) |
| I Am Banking On The Silver Tsunami With Big Dividends |
There are sectors that experience demand irrespective of economic climate. I like cold hard cash placed in my account. We discuss big dividends from healthcare, yields +8.3%. |
seekingalpha.com |
2024-10-12 14:30:00 |
Czytaj oryginał (ang.) |
| Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? |
Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-10-04 12:51:12 |
Czytaj oryginał (ang.) |
| Harrow Relaunches TRIESENCE® |
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative‑free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. In commenting on the announcement, Mar. |
businesswire.com |
2024-10-03 11:00:00 |
Czytaj oryginał (ang.) |
| Harrow Inc (HROW) Shares Up 3.26% on Oct 2 |
Shares of Harrow Inc (HROW, Financial) surged 3.26% in mid-day trading on Oct 2. The stock reached an intraday high of $46.10, before settling at $45.90, up from its previous close of $44.45. |
gurufocus.com |
2024-10-02 16:10:23 |
Czytaj oryginał (ang.) |